Combination lenalidomide‐rituximab immunotherapy activates anti‐tumour immunity and induces tumour cell death by complementary mechanisms of action in follicular lymphoma

Summary Chemotherapy plus rituximab has been the mainstay of treatment for follicular lymphoma (FL) for two decades but is associated with immunosuppression and relapse. In phase 2 studies, lenalidomide combined with rituximab (R2) has shown clinical synergy in front‐line and relapsed/refractory FL....

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:British journal of haematology 2019-04, Vol.185 (2), p.240-253
Hauptverfasser: Chiu, Hsiling, Trisal, Preeti, Bjorklund, Chad, Carrancio, Soraya, Toraño, Estela G., Guarinos, Carla, Papazoglou, Despoina, Hagner, Patrick R., Beldi‐Ferchiou, Asma, Tarte, Karin, Delfau‐Larue, Marie‐Hélène, Morschhauser, Franck, Ramsay, Alan G., Gandhi, Anita K.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!